Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 12/20 | 0.47 |
| ▸ | PDE4D | Q08499 | 11/20 | 0.47 |
| ▸ | PDE4B | Q07343 | 4/20 | 0.47 |
| ▸ | PDE4C | Q08493 | 4/20 | 0.47 |
| ▸ | PDE3B | Q13370 | 2/20 | 0.47 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.47 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3608828 | 1.00 | PDE4A (0.47) | PDE4APDE4DPDE4BPDE4CPDE3B | |
| SCHEMBL13343032 | 0.91 | PDE4A (0.52) | PDE4APDE4DPDE4BPDE4CPDE3B | |
| SCHEMBL13343030 | 0.91 | PDE4A (0.52) | PDE4APDE4DPDE4BPDE4CPDE3B | |
| SCHEMBL13342941 | 0.87 | PDE4A (0.47) | PDE4APDE4DPDE4BPDE4CPDE3B | |
| SCHEMBL3607505 | 0.87 | PDE4A (0.47) | PDE4APDE4DPDE4BPDE4CPDE3B | |
| SCHEMBL13342970 | 0.86 | ALDH1A1 (0.49) | PDE4APDE4DPDE4BPDE4CPDE3B | |
| SCHEMBL3605210 | 0.86 | ALDH1A1 (0.49) | PDE4APDE4DPDE4BPDE4CPDE3B | |
| SCHEMBL3598825 | 0.86 | PDE4D (0.50) | PDE4APDE4DPDE4BPDE4CPDE3B | |
| SCHEMBL3616052 | 0.85 | PDE4A (0.45) | PDE4APDE4DPDE4BPDE4CPDE3B | |
| SCHEMBL13342922 | 0.85 | PDE4A (0.45) | PDE4APDE4DPDE4BPDE4CPDE3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7723348-B2 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORPORATION (US) | 2010-05-25 | — | — | US | disclosed |
| US-7723348-B2 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORPORATION (US) | 2010-05-25 | — | — | US | disclosed |
| US-20080207660-A1 | PHOSPHODIESTERASE 4 INHIBITORS | HOPPER ALLEN | 2008-08-28 | — | — | US | disclosed |
| US-20080207660-A1 | PHOSPHODIESTERASE 4 INHIBITORS | HOPPER ALLEN | 2008-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207660-A1 | PHOSPHODIESTERASE 4 INHIBITORS | PDE4A, PDE4B, PDE12 | PDE4A 1/4885PDE4D 6/4885PDE4B 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.